Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels.
The use of block copolymer micelles (BCMs) for the targeted delivery of chemotherapeutics has proven to be a promising approach for improving the therapeutic efficacy of pharmaceutical cancer therapy. Acceleration of the translation of BCM-based drug formulations from the fundamental stages of pre-clinical development to clinical use requires a greater understanding of the transport mechanisms that influence the fate of these nano-carrier systems at the whole body, tissue, and cellular levels. New information emerging regarding the intratumoral distribution, and tumor penetration of BCMs and other nanosystems in vivo, by non-invasive image-based assessment, has the potential to revolutionize our understanding and current approach to drug delivery in this field. This review aims to highlight these and other important advancements as well as to bring attention to the many critical questions that remain to be addressed regarding the fate of BCM-based drug formulations in vivo.
Leslie Dan Faculty of Pharmacy, Institute Biomaterials and Biomedical Engineering, University of Toronto, 144 College Street, Toronto, Ontario, Canada.
Andrew S
AS
Mikhail
Christine
C
Allen
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008823:Micelles; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy*; D011108:Polymers / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008823:Micelles; D011108:Polymers